| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2008;51:797.)
© 2008 American Heart Association, Inc.
Original Articles |
From the Life Science and Bioethics Research Center (S.H., M.O., M.Y.) and Department of Geriatrics and Vascular Medicine, Graduate School of Medicine (S.H., K.S.), Tokyo Medical and Dental University, Tokyo, Japan.
Correspondence Masayuki Yoshida, Life Science and Bioethics Research Center, Tokyo Medical and Dental University, 1-5-45 Yushima Building D-809, Bunkyo-ku, Tokyo 113-8519, Japan. E-mail masavasc{at}tmd.ac.jp
| Abstract |
|---|
|
|
|---|
Key Words: angiotensin receptors imaging inflammation oxidant stress leukocytes
| Introduction |
|---|
|
|
|---|
Leukocyte recruitment to the site of inflamed vasculature, one of the critical mechanisms in the acute phase after injury, is a complex cascade of events in which various adhesion molecules and chemokines are involved.13,14 Recently, our group established a novel intravital microscopy (IVM) system to observe and analyze leukocyte adhesion in the mechanically injured femoral artery in the mouse.15 Using this novel experimental system, we were able to discover a biphasic temporal pattern of leukocyte recruitment after injury and to investigate in detail the early phase of atherosclerosis-prone vascular injury.15 In the present study, we examined the potential contribution of oxidative stress and its modulation by olmesartan, an ARB, in leukocyte recruitment to the mechanically injured femoral artery, as well as adoptive transfer of peripheral mononuclear cells (MNCs) and polymorphonuclear cells (PMNs) from olmesartan-treated mice into control mice or vice versa to examine the role of specific cell populations that contribute to ARB-sensitive leukocyte adhesion.
| Materials and Methods |
|---|
|
|
|---|
| Results |
|---|
|
|
|---|
Effect of Olmesartan in Leukocyte Recruitment After Injury
Representative snapshots (Figure 1A) and video movies (Figures S2 to S5) of dynamic adhesive interaction of leukocytes to the mechanically injured femoral artery revealed that leukocyte recruitment toward the injured artery of the control animal was significantly increased 24 hours (24.25±1.59 cells per 104 µm2 of vessel surface; n=10) and 7 days (28.38±3.38 cells per 104 µm2 of vessel surface) after injury (open columns, Figure 1B). In contrast, olmesartan treatment significantly reduced the adhesion of leukocytes to the injured artery at 24 hours (7.42±1.02 cells per 104 µm2 of vessel surface) and 7 days (13.00±0.83 cells per 104 µm2 of vessel surface) after injury (solid columns, Figure 1B). The rolling velocity of leukocytes, an important parameter for rolling interaction, significantly increased in the olmesartan treatment group as compared with the control group (Figure 1C), although the rolling influx was not significantly changed between these 2 groups (data not shown). Olmesartan inhibited the intimal hyperplasia of the murine femoral artery at 28 days after mechanical injury (Figure S6), as reported previously.8
|
Role of Oxidative Stress in Leukocyte Recruitment After Vascular Injury
Because oxidative stress has been shown to play a pivotal role in vascular injury, we estimated its level by infusing dihydroethidium (DHE), a fluorescence probe used to detect an oxidative stress. As shown in Figures 2A and 2B, vascular injury significantly increased DHE-sensitive oxidative stress, which was blunted by olmesartan treatment at 24 hours, as well as 7 days after injury. To confirm the contribution of a reduction of oxidative stress in antiadhesive property of olmesartan, we examined the effect of apocynin, a free radical scavenger. As clearly shown in snapshot pictures (Figure 3A) and their quantifications (Figure 3B), the number of leukocytes adhered to the vascular wall was significantly lower in the apocynin-treated group (apcy) as compared with the group treated with vehicle at 24 hours (group treated with vehicle, 20.45±3.66 cells per 104 µm2 of vessel surface; apcy, 10.22±0.95 cells per 104 µm2 of vessel surface; n=10; P<0.05) and 7 days (group treated with vehicle, 22.21±4.45 cells per 104 µm2 of vessel surface; apcy, 13.83±1.56 cells per 104 µm2 of vessel surface; n=6). Rolling velocity was also similarly increased to that in the olmesartan group (Figure 3C). As expected, apocynin inhibited injury-induced oxidative stress in vasculature both at 24 hours and 7 days after injury (Figure 3D).
|
|
Olmesartan Treatment on Leukocytes, but Not of the Vasculature, Inhibits Leukocyte Recruitment to the Injured Femoral Artery
To determine whether olmesartan affects the leukocytes or the injured vascular tissues, we performed adoptive transfer of peripheral MNCs. First, MNCs from nontreated mice were harvested 24 hours after wire injury, labeled ex vivo with Rhodamine 6G, and administered intravenously into nontreated recipient mice with wire injury. As shown in Figure 4A, it led to significant leukocyte recruitment in the recipient femoral artery. In contrast, when MNCs, prepared from nontreated mice without wire injury, were infused into nontreated recipient mice with wire injury, MNC recruitment was significantly reduced even though the recipient artery was injured comparably (Figure 4B). This finding reveals a dominant role of MNCs, but not vasculature, in mediating MNC recruitment to the mechanically injured artery. Next, we examined a potential effect of olmesartan in MNCs and in the injured vasculature. When MNCs harvested from mice treated with olmesartan were infused into recipient mice, MNC recruitment in the recipient injured artery was significantly inhibited (Figure 4C). In contrast, when MNCs prepared from mice without olmesartan were injected into recipient mice with olmesartan, significant MNC recruitment was observed (Figure 4D). Quantitative analyses confirmed our findings (Figure 4E). Similar inhibitory effects for MNCs were also confirmed with apocynin (Figure 4E).
|
To check potential contribution of neutrophils (PMNs) in observed leukocyte adhesion after injury, we prepared PMNs from mice treated with or without olmesartan and transferred them to those without olmesartan treatment at 24 hours and 7 days after injury (Figure 5) and compared them with the effects for MNCs. MNCs exhibited similar levels of adhesion to the injured vasculature at both 24 hours and 7 days after injury, which was significantly reduced when MNCs were prepared from those treated with olmesartan. In contrast, adhesion of PMN was prominent at 24 hours but not 7 days after injury. Olmesartan treatment significantly reduced PMN adhesion at 24 hours after injury (Figure 5).
|
Oxidative Stress and Integrin Expression in Circulating Leukocytes
To detect the increase of oxidative stress in MNCs in the injured mice, we performed flow cytometry for DHE. As shown in Figure 6A, DHE-associated fluorescence intensity in MNCs was increased after mechanical injury and reduced after olmesartan treatment. Furthermore, we analyzed the expression levels of cell surface CD11b, a member of the integrin family of adhesion molecules. As shown in Figure 6B, the expression level of CD11b was increased after mechanical injury and reduced after olmesartan treatment. Apocynin-treated MNCs also exhibited reduction of DHE staining, as well as CD11b expression.
|
| Discussion |
|---|
|
|
|---|
We further tried to define the specific cell populations responsible for the mechanical injury–induced leukocyte recruitment and its blockade by olmesartan. Despite its importance in the vascular wall, the oxidative stress in circulating MNCs had not been carefully studied until recent observation of the microvasculature of hypercholesterolemic mice,12 in which the importance of the Ang II type 1 receptor on leukocytes was addressed for the first time. Indeed, although MNCs from injured mice exhibited significant adhesion to the recipient injured artery, MNCs taken from mice without wire injury failed to adhere to the injured artery (Figures 4B and 4C), suggesting a dominant role of MNCs in leukocyte recruitment to the femoral artery after injury. We also observed a significant adhesion of PMN at 24 hours but not 7 days after injury, suggesting a contribution of PMNs in the acute phase of injury, although their number is relatively small (
15% of peripheral leukocytes26) in mice. The temporal pattern of adhesive interaction of PMNs was parallel to the reduction of oxidative stress at the vasculature (Figure 5), suggesting their role as a source of oxidative stress at the acute phase of vascular injury.27
Although our model demonstrated a pattern of leukocyte recruitment after vascular injury, there is a substantial difference between leukocyte recruitment observed in hypercholesterolemic mice where leukocytes interact with endothelial cells and that observed in mechanically injured mice where leukocytes interact with the denuded vascular wall. Nonetheless, our observations, in which circulating MNCs play an important role, represent a novel insight in the pathophysiology of vascular injury, such as percutaneous coronary intervention. Similarly, the antiadhesive effect of olmesartan was prominent in MNCs when compared with its effect on vascular cells. In fact, oxidative stress in MNCs was significantly elevated after wire injury and inhibited when olmesartan was administered (Figure 6A). Although the precise molecular mechanisms responsible for the generation of oxidative stress in MNCs were not known, the moderate upregulation of CD11b (Figure 6B) supported our adhesion data. As reported previously, oxidative stress has been shown to enhance CD11b expression in THP-1 cells treated with nonesterified fatty acids, primarily through the nicotinamide-adenine dinucleotide phosphate oxidase–dependent pathway.28 Because we observed cell adhesion after intimal denudation, we should examine other atherosclerosis models without luminal injury to monitor leukocyte adhesion to the vascular wall in the presence of an endothelial layer to understand leukocyte adhesion during the atherogenesis process.
Perspectives
We observed that olmesartan, an ARB, inhibits leukocyte recruitment as early as 24 hours after the mechanical injury of the femoral artery via the modulation of oxidative stress in MNCs. Our findings provide a novel insight to postulate a broader role for oxidative stress in mediating adhesive interaction to vascular injuries and a potential application of olmesartan as a treatment in the early phase of vascular injury to prevent inflammatory responses.
| Acknowledgments |
|---|
Sources of Funding
This study was supported in part by a Grant-in-Aid from the Ministry of Education, Science, Sports, and Culture of Japan (18590805).
Disclosures
None.
Received July 30, 2007; first decision August 20, 2007; accepted December 19, 2007.
| References |
|---|
|
|
|---|
2. Suzuki J, Iwai M, Nakagami H, Wu L, Chen R, Sugaya T, Hamada M, Hiwada K, Horiuchi M. Role of angiotensin II-regulated apoptosis through distinct AT1 and AT2 receptors in neointimal formation. Circulation. 2002; 106: 847–853.
3. Alvarez A, Sanz MJ. Reactive oxygen species mediate angiotensin II-induced leukocyte-endothelial cell interactions in vivo. J Leukoc Biol. 2001; 70: 199–206.
4. Piqueras L, Kubes P, Alvarez A, OConnor E, Issekutz AC, Esplugues JV, Sanz MJ. Angiotensin II induces leukocyte-endothelial cell interactions in vivo via AT(1) and AT(2) receptor-mediated P-selectin upregulation. Circulation. 2000; 102: 2118–2123.
5. Parmentier JH, Zhang C, Estes A, Schaefer S, Malik KU. Essential role of PKC-zeta in normal and angiotensin II-accelerated neointimal growth after vascular injury. Am J Physiol Heart Circ Physiol. 2006; 291: H1602–H1613.
6. Chen R, Iwai M, Wu L, Suzuki J, Min LJ, Shiuchi T, Sugaya T, Liu HW, Cui TX, Horiuchi M. Important role of nitric oxide in the effect of angiotensin-converting enzyme inhibitor imidapril on vascular injury. Hypertension. 2003; 42: 542–547.
7. Jinno T, Iwai M, Li Z, Li J-M, Liu H-W, Cui T-X, Rakugi H, Ogihara T, Horiuchi M. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Hypertension. 2004; 43: 263–269.
8. Ohtani K, Egashira K, Ihara Y, Nakano K, Funakoshi K, Zhao G, Sata M, Sunagawa K. Angiotensin II type 1 receptor blockade attenuates in-stent restenosis by inhibiting inflammation and progenitor cells. Hypertension. 2006; 48: 664–670.
9. Griendling KK, Murphy TJ, Alexander RW. Molecular biology of the renin-angiotensin system. Circulation. 1993; 87: 1816–1828.
10. Warnholtz A, Nickenig G, Schulz E, Macharzina R, Brasen JH, Skatchkov M, Heitzer T, Stasch JP, Griendling KK, Harrison DG, Bohm M, Meinertz T, Munzel T. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation. 1999; 99: 2027–2033.
11. Stokes KY, Clanton EC, Russell JM, Ross CR, Granger DN. NAD(P)H oxidase-derived superoxide mediates hypercholesterolemia-induced leukocyte-endothelial cell adhesion. Circ Res. 2001; 88: 499–505.
12. Petnehazy T, Stokes KY, Wood KC, Russell J, Granger DN. Role of blood cell-associated AT1 receptors in the microvascular responses to hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2006; 26: 313–318.
13. Bevilacqua MP, Nelson RM, Mannori G, Cecconi O. Endothelial-leukocyte adhesion molecules in human disease. Annu Rev Med. 1994; 45: 361–378.[CrossRef][Medline] [Order article via Infotrieve]
14. Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA Jr, Luster AD, Luscinskas FW, Rosenzweig A. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature. 1999; 398: 718–723.[CrossRef][Medline] [Order article via Infotrieve]
15. Osaka M, Hagita S, Haraguchi M, Kajimura M, Suematsu M, Yoshida M. Real time imaging of mechanically injured-femoral artery in mouse revealed a biphasic pattern of leukocyte accumulation. Am J Physiol Heart Circ Physiol. 2007; 292: H1876–H1882.
16. Riaz AA, Wang Y, Schramm R, Sato T, Menger MD, Jeppsson B, Thorlacius H. Role of angiotensin II in ischemia/reperfusion-induced leukocyte-endothelium interactions in the colon. FASEB J. 2004; 18: 881–883.
17. Alvarez A, Hermenegildo C, Issekutz AC, Esplugues JV, Sanz MJ. Estrogens inhibit angiotensin II-induced leukocyte-endothelial cell interactions in vivo via rapid endothelial nitric oxide synthase and cyclooxygenase activation. Circ Res. 2002; 91: 1142–1150.
18. Alvarez A, Piqueras L, Bello R, Canet A, Moreno L, Kubes P, Sanz MJ. Angiotensin II is involved in nitric oxide synthase and cyclo-oxygenase inhibition-induced leukocyte-endothelial cell interactions in vivo. Br J Pharmacol. 2001; 132: 677–684.[CrossRef][Medline] [Order article via Infotrieve]
19. Barry-Lane PA, Patterson C, van der Merwe M, Hu Z, Holland SM, Yeh ET, Runge MS. p47phox is required for atherosclerotic lesion progression in ApoE(–/–) mice. J Clin Invest. 2001; 108: 1513–1522.[CrossRef][Medline] [Order article via Infotrieve]
20. Tsuda M, Iwai M, Li JM, Li HS, Min LJ, Ide A, Okumura M, Suzuki J, Mogi M, Suzuki H, Horiuchi M. Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress. Hypertension. 2005; 45: 545–551.
21. Vendrov AE, Madamanchi NR, Hakim ZS, Rojas M, Runge MS. Thrombin and NAD(P)H oxidase-mediated regulation of CD44 and BMP4-Id pathway in VSMC, restenosis, and atherosclerosis. Circ Res. 2006; 98: 1254–1263.
22. Oshita A, Iwai M, Chen R, Ide A, Okumura M, Fukunaga S, Yoshii T, Mogi M, Higaki J, Horiuchi M. Attenuation of inflammatory vascular remodeling by angiotensin II type 1 receptor-associated protein. Hypertension. 2006; 48: 671–676.
23. Liu JJ, Song CW, Yue Y, Duan CG, Yang J, He T, He YZ. Quercetin inhibits LPS-induced delay in spontaneous apoptosis and activation of neutrophils. Inflamm Res. 2005; 54: 500–507.[CrossRef][Medline] [Order article via Infotrieve]
24. Deem TL, Cook-Mills JM. Vascular cell adhesion molecule 1 (VCAM-1) activation of endothelial cell matrix metalloproteinases: role of reactive oxygen species. Blood. 2004; 104: 2385–2393.
25. Basta G, Lazzerini G, Del Turco S, Ratto GM, Schmidt AM, De Caterina R. At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation end products. Arterioscler Thromb Vasc Biol. 2005; 25: 1401–1407.
26. Mencacci A, Montagnoli C, Bacci A, Cenci E, Pitzurra L, Spreca A, Kopf M, Sharpe AH, Romani L. CD80+Gr-1+ myeloid cells inhibit development of antifungal Th1 immunity in mice with candidiasis. J Immunol. 2002; 169: 3180–3190.
27. Kaminski KA, Bonda TA, Korecki J, Musial WJ. Oxidative stress and neutrophil activation–the two keystones of ischemia/reperfusion injury. Int J Cardiol. 2002; 86: 41–59.[CrossRef][Medline] [Order article via Infotrieve]
28. Zhang W-Y, Schwartz E, Wang Y, Attrep J, Li Z, Reaven P. Elevated concentrations of nonesterified fatty acids increase monocyte expression of CD11b and adhesion to endothelial cells. Arterioscler Thromb Vasc Biol. 2006; 26: 514–519.
This article has been cited by other articles:
![]() |
J. Ino, C. Kojima, M. Osaka, K. Nitta, and M. Yoshida Dynamic Observation of Mechanically-Injured Mouse Femoral Artery Reveals an Antiinflammatory Effect of Renin Inhibitor Arterioscler Thromb Vasc Biol, November 1, 2009; 29(11): 1858 - 1863. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |